StockNews.com started coverage on shares of Tonix Pharmaceuticals (NASDAQ:TNXP – Free Report) in a report released on Sunday morning. The firm issued a sell rating on the stock.
Separately, Alliance Global Partners increased their price objective on shares of Tonix Pharmaceuticals from $6.00 to $11.00 and gave the company a “buy” rating in a research note on Monday, July 22nd.
Get Our Latest Stock Report on Tonix Pharmaceuticals
Tonix Pharmaceuticals Trading Down 5.2 %
Tonix Pharmaceuticals (NASDAQ:TNXP – Get Free Report) last announced its earnings results on Friday, August 16th. The company reported ($19.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($9.91) by ($9.37). The company had revenue of $2.21 million for the quarter, compared to analysts’ expectations of $3.50 million. Tonix Pharmaceuticals had a negative net margin of 1,196.11% and a negative return on equity of 158.27%. As a group, research analysts predict that Tonix Pharmaceuticals will post -18 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Tonix Pharmaceuticals
A hedge fund recently raised its stake in Tonix Pharmaceuticals stock. Acadian Asset Management LLC increased its stake in shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP – Free Report) by 260.6% in the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 335,373 shares of the company’s stock after buying an additional 242,358 shares during the period. Acadian Asset Management LLC owned about 0.40% of Tonix Pharmaceuticals worth $61,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 82.26% of the company’s stock.
About Tonix Pharmaceuticals
Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.
Featured Stories
- Five stocks we like better than Tonix Pharmaceuticals
- Retail Stocks Investing, Explained
- How Verizon Could Offer Stress-Free Double-Digit Returns in 2025
- 3 Small Caps With Big Return Potential
- Can Roche Challenge Lilly and Novo in the Weight Loss Market?
- How to Most Effectively Use the MarketBeat Earnings Screener
- Roblox Stock: Key Metrics Surge, Is This the Perfect Entry?
Receive News & Ratings for Tonix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tonix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.